119 related articles for article (PubMed ID: 26757112)
1. Cytotoxicity of and DNA adduct formation by ellipticine and its micellar form in human leukemia cells in vitro.
Stiborova M; Manhartova Z; Hodek P; Adam V; Kizek R; Eckschlager T; Frei E
Neuro Endocrinol Lett; 2015; 36 Suppl 1():22-8. PubMed ID: 26757112
[TBL] [Abstract][Full Text] [Related]
2. Formation of DNA adducts by ellipticine and its micellar form in rats - a comparative study.
Stiborova M; Manhartova Z; Hodek P; Adam V; Kizek R; Frei E
Sensors (Basel); 2014 Dec; 14(12):22982-97. PubMed ID: 25479328
[TBL] [Abstract][Full Text] [Related]
3. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.
Poljaková J; Frei E; Gomez JE; Aimová D; Eckschlager T; Hrabeta J; Stiborová M
Cancer Lett; 2007 Jul; 252(2):270-9. PubMed ID: 17306925
[TBL] [Abstract][Full Text] [Related]
4. Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
Stiborova M; Poljakova J; Eckschlager T; Kizek R; Frei E
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):115-21. PubMed ID: 22837132
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
Martinkova E; Dontenwill M; Frei E; Stiborova M
Neuro Endocrinol Lett; 2009; 30 Suppl 1():60-6. PubMed ID: 20027146
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
[TBL] [Abstract][Full Text] [Related]
7. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
Stiborová M; Breuer A; Aimová D; Stiborová-Rupertová M; Wiessler M; Frei E
Int J Cancer; 2003 Dec; 107(6):885-90. PubMed ID: 14601046
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine.
Sulc M; Mrizova I; Cerna T; Frei E; Eckschlager T; Adam V; Kopeckova K; Stiborova M
Neuro Endocrinol Lett; 2016 Dec; 37(Suppl1):95-102. PubMed ID: 28263536
[TBL] [Abstract][Full Text] [Related]
9. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.
Stiborová M; Rupertová M; Aimová D; Ryslavá H; Frei E
Toxicology; 2007 Jul; 236(1-2):50-60. PubMed ID: 17482743
[TBL] [Abstract][Full Text] [Related]
10. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.
Frei E; Bieler CA; Arlt VM; Wiessler M; Stiborová M
Biochem Pharmacol; 2002 Jul; 64(2):289-95. PubMed ID: 12123750
[TBL] [Abstract][Full Text] [Related]
11. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
Aimová D; Svobodová L; Kotrbová V; Mrázová B; Hodek P; Hudecek J; Václavíková R; Frei E; Stiborová M
Drug Metab Dispos; 2007 Oct; 35(10):1926-34. PubMed ID: 17656468
[TBL] [Abstract][Full Text] [Related]
12. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.
Stiborová M; Bieler CA; Wiessler M; Frei E
Biochem Pharmacol; 2001 Dec; 62(12):1675-84. PubMed ID: 11755121
[TBL] [Abstract][Full Text] [Related]
13. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
[TBL] [Abstract][Full Text] [Related]
14. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.
Stiborová M; Poljaková J; Ryslavá H; Dracínský M; Eckschlager T; Frei E
Int J Cancer; 2007 Jan; 120(2):243-51. PubMed ID: 17066455
[TBL] [Abstract][Full Text] [Related]
15. Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells.
Indra R; Černá T; Heger Z; Hraběta J; Wilhelm M; Dostálová S; Lengálová A; Martínková M; Adam V; Eckschlager T; Schmeiser HH; Arlt VM; Stiborová M
Toxicology; 2019 May; 419():40-54. PubMed ID: 30914192
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.
Stiborová M; Rupertová M; Frei E
Biochim Biophys Acta; 2011 Jan; 1814(1):175-85. PubMed ID: 20576524
[TBL] [Abstract][Full Text] [Related]
17. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
[TBL] [Abstract][Full Text] [Related]
18. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.
Stiborová M; Stiborová-Rupertová M; Borek-Dohalská L; Wiessler M; Frei E
Chem Res Toxicol; 2003 Jan; 16(1):38-47. PubMed ID: 12693029
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.
Stiborova M; Rupertova M; Schmeiser HH; Frei E
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2006 Jul; 150(1):13-23. PubMed ID: 16936898
[TBL] [Abstract][Full Text] [Related]
20. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
